Nagakawa Osamu, Yamagishi Toshiya, Akashi Takuya, Nagaike Kazuhiro, Fuse Hideki
Toyama Medical and Pharmaceutical University, Department of Urology, Toyama, Japan.
Prostate. 2006 Apr 1;66(5):447-52. doi: 10.1002/pros.20301.
Hepatocyte growth factor activator inhibitor type 1 (HAI-1) and type 2 (HAI-2) are Kunitz-type serine protease inhibitors for hepatocyte growth factor activator (HGFA). We attempted to clarify whether serum levels of HAI-1 and HAI-2 could be a useful marker in patients with prostate cancer.
Serum levels of HAI-1 and HAI-2 were measured by enzyme-linked immunosorbent assay in 27 patients with benign prostatic hyperplasia (BPH) and 118 patients with prostate cancer.
The mean serum levels of HAI-1 in patients with prostate cancer were significantly higher than those in patients with BPH. Furthermore, the serum HAI-1 levels in patients with distant metastasis and hormone resistant prostate cancer were significantly elevated compared with those in patients with organ-confined diseases. There were no significant differences in serum HAI-2 levels among prostate cancer subgroups according to clinical stage. Significantly elevated levels of HAI-1 were detected in 38 patients with prostate cancer before any treatment.
HAI-1 may be a potential tumor marker for prostate cancer. Further studies in large groups of patients are needed to define the clinical value of HAI-1.
1型肝细胞生长因子激活物抑制剂（HAI-1）和2型肝细胞生长因子激活物抑制剂（HAI-2）是肝细胞生长因子激活物（HGFA）的Kunitz型丝氨酸蛋白酶抑制剂。我们试图阐明HAI-1和HAI-2的血清水平是否可作为前列腺癌患者的有用标志物。
采用酶联免疫吸附测定法检测27例良性前列腺增生（BPH）患者和118例前列腺癌患者血清中HAI-1和HAI-2的水平。
前列腺癌患者血清HAI-1的平均水平显著高于BPH患者。此外，远处转移和激素抵抗性前列腺癌患者的血清HAI-1水平显著高于局限性疾病患者。根据临床分期，前列腺癌亚组之间的血清HAI-2水平无显著差异。在38例未经任何治疗的前列腺癌患者中检测到HAI-1水平显著升高。
HAI-1可能是前列腺癌的潜在肿瘤标志物。需要对大量患者进行进一步研究以确定HAI-1的临床价值。
